

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Company Registration No. 200505118M)

STRIKING OFF OF DORMANT SUBSIDIARIES

*Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings as defined in the announcement released on 30 August 2016 in respect of the incorporation of the Joint Venture Companies (the “**Previous Announcement**”).*

1. The board of directors (the “**Board**” of the “**Directors**”) of China Medical (International) Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) wishes to announce the deregistration of its wholly-owned and indirect subsidiaries in the Hong Kong Special Administrative Region of the People’s Republic of China (“**Hong Kong**”).
2. The Group’s operations in Hong Kong remained weak. In this regard, the Group does not foresee improvement in the immediate future. Accordingly, the Company is currently reviewing the available options and have applied to deregister the following entities to cut costs:
 - 2.1. CMIG Ren Feng Medical (Futian) Limited (“**CMIG Futian**”), a 50% owned subsidiary of China Medical Services (Hong Kong) Limited, which is in turn a wholly owned subsidiary of the Company. CMIG Futian was incorporated as a joint venture company in 2018 but has remained dormant due to the reasons set out in paragraph 2;
 - 2.2. CMIG Ren Feng Medical (Nanshan) Limited (“**CMIG Nanshan**”), a 50% owned subsidiary of China Medical Services (Hong Kong) Limited, which is in turn a wholly owned subsidiary of the Company. CMIG Nanshan was incorporated as a joint venture company in 2018 but has remained dormant due to the reasons set out in paragraph 2;
 - 2.3. CMIG Ren Feng Med-Biotechnology Limited (“**CMIG Med-Bio**”), a 50% owned subsidiary of China Medical Services (Hong Kong) Limited, which is in turn a wholly owned subsidiary of the Company. CMIG Med-Bio was incorporated as a joint venture company in 2018 but has remained dormant due to the reasons set out in paragraph 2;
 - 2.4. CMIG GY Sales Limited (“**CMIG GY**”), 51% owned subsidiary of China Medical Services (Hong Kong) Limited, which is in turn a wholly owned subsidiary of the Company. CMIG GY was incorporated as a joint venture company in 2018 but has remained dormant due to the reasons set out in paragraph 2;
 - 2.5. CMIG Medical Services (Hong Kong) Limited (“**CMIG Medical Services**”), a wholly owned subsidiary of the Company. CMIG Medical Services has remained dormant due to the reasons set out in paragraph 2;
 - 2.6. CMIG Medical Clinics (Hong Kong) Limited (“**CMIG Medical Clinics**”), a wholly owned subsidiary of the Company. CMIG Medical Clinics has remained dormant due to the reasons set out in paragraph 2; and
 - 2.7. China iMyth (Hong Kong) Limited (“**China iMyth**”), a 51% owned subsidiary of China iMyth Company Pte. Ltd., which is in turn 51% owned by the Company. China iMyth has remained dormant due to the reasons set out in paragraph 2.

3. The deregistration of CMIG Futian, CMIG Nanshan, CMIG Med-Bio, CMIG GY, China Medical Services, CMIG Medical Clinics and China iMyth are not expected to have any material impact on the consolidated net tangible assets and earnings per share of the Company and the Group for the financial year ending 31 December 2018.
4. Save as disclosed above, none of the Directors or substantial shareholders of the Company, as well as their respective associates, has any interest, direct or indirect, in the abovementioned transactions (other than through their interests in the shares of the Company).
5. In the meantime, the Group will undertake a review of its existing operations and intensify the search for and pursue opportunities for growth and will update shareholders should there be any material developments.

BY ORDER OF THE BOARD

5 November 2018

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).